Literature DB >> 24680743

Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease.

Anil Kachroo1, Michael A Schwarzschild2.   

Abstract

Robust epidemiological data link higher levels of the antioxidant urate to a reduced risk of developing Parkinson׳s disease (PD) and to a slower rate of its progression. Allopurinol, an inhibitor of xanthine oxidoreductase (XOR), blocks the oxidation of xanthine to urate. The present study sought to determine whether lowering levels of urate using allopurinol results in exacerbated neurotoxicity in a dual pesticide mouse model of PD. Although oral allopurinol reduced serum and striatal urate levels 4-fold and 1.3-fold, respectively, it did not alter the multiple motor deficits induced by chronic (7 week) intermittent (biweekly) exposure to intraperitoneal Paraquat (PQ) plus Maneb (MB). However, striatal dopamine content, which was unaffected after either allopurinol or chronic pesticide exposure alone, was significantly reduced by 22% in mice exposed to the combination. Stereological assessment showed that the numbers of dopaminergic nigral neurons were significantly reduced by 29% and the tyrosine hydroxylase (TH) negative neurons unaffected after PQ+MB treatments. This reduction in TH-positive neurons was not affected by allopurinol treatment. Of note, despite the expectation of exacerbated oxidative damage due to the reduction in urate, protein carbonyl levels, a marker of oxidative damage, were actually reduced in the presence of allopurinol. Overall, allopurinol lowered urate levels but did not exacerbate dopaminergic neuron degeneration, findings suggesting that basal levels of urate in mice do not appreciably protect against oxidative damage and neurotoxicity in the PQ+MB model of PD, and/or that allopurinol produces an antioxidant benefit offsetting its detrimental urate-lowering effect.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allopurinol; Maneb; Paraquat; Parkinson׳s disease; Urate

Mesh:

Substances:

Year:  2014        PMID: 24680743      PMCID: PMC4146456          DOI: 10.1016/j.brainres.2014.03.031

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  29 in total

1.  Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.

Authors:  Wenzhen Duan; Bruce Ladenheim; Roy G Cutler; Inna I Kruman; Jean Lud Cadet; Mark P Mattson
Journal:  J Neurochem       Date:  2002-01       Impact factor: 5.372

2.  Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells.

Authors:  D C Jones; P G Gunasekar; J L Borowitz; G E Isom
Journal:  J Neurochem       Date:  2000-06       Impact factor: 5.372

3.  Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.

Authors:  Anil Kachroo; Michael A Schwarzschild
Journal:  Ann Neurol       Date:  2012-02       Impact factor: 10.422

4.  Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

Authors:  J F Chen; K Xu; J P Petzer; R Staal; Y H Xu; M Beilstein; P K Sonsalla; K Castagnoli; N Castagnoli; M A Schwarzschild
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

5.  Vascular and hepatocellular peroxynitrite formation during acetaminophen toxicity: role of mitochondrial oxidant stress.

Authors:  T R Knight; A Kurtz; M L Bajt; J A Hinson; H Jaeschke
Journal:  Toxicol Sci       Date:  2001-08       Impact factor: 4.849

6.  Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors.

Authors:  Gwen S Scott; Sergei V Spitsin; Rhonda B Kean; Tatiana Mikheeva; Hilary Koprowski; D Craig Hooper
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-25       Impact factor: 11.205

7.  The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease.

Authors:  M Thiruchelvam; E K Richfield; R B Baggs; A W Tank; D A Cory-Slechta
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

Review 8.  Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma.

Authors:  Kyung-Jin Yeum; Robert M Russell; Norman I Krinsky; Giancarlo Aldini
Journal:  Arch Biochem Biophys       Date:  2004-10-01       Impact factor: 4.013

Review 9.  Structure and function of xanthine oxidoreductase: where are we now?

Authors:  Roger Harrison
Journal:  Free Radic Biol Med       Date:  2002-09-15       Impact factor: 7.376

Review 10.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.

Authors:  Cristine E Berry; Joshua M Hare
Journal:  J Physiol       Date:  2003-12-23       Impact factor: 5.182

View more
  5 in total

1.  The significance of serum uric acid level in humans with acute paraquat poisoning.

Authors:  JuanWen Zhang; Ying Zhao; YunJuan Bai; GuoCai Lv; JianPing Wu; Yu Chen
Journal:  Sci Rep       Date:  2015-03-16       Impact factor: 4.379

2.  Glut9-mediated Urate Uptake Is Responsible for Its Protective Effects on Dopaminergic Neurons in Parkinson's Disease Models.

Authors:  Mingxia Bi; Qian Jiao; Xixun Du; Hong Jiang
Journal:  Front Mol Neurosci       Date:  2018-01-26       Impact factor: 5.639

3.  Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment.

Authors:  Xian-Si Zeng; Wen-Shuo Geng; Jin-Jing Jia
Journal:  ASN Neuro       Date:  2018 Jan-Dec       Impact factor: 4.146

4.  Allopurinol Lowers Serum Urate but Does Not Reduce Oxidative Stress in CKD.

Authors:  Mingyao Sun; Nicole Hines; Diego Scerbo; Jane Buchanan; Chaorong Wu; Patrick Ten Eyck; Diana Zepeda-Orozco; Eric B Taylor; Diana I Jalal
Journal:  Antioxidants (Basel)       Date:  2022-06-29

5.  Comparative Proteomic Analysis of Carbonylated Proteins from the Striatum and Cortex of Pesticide-Treated Mice.

Authors:  Christina Coughlan; Douglas I Walker; Kelly M Lohr; Jason R Richardson; Laura M Saba; W Michael Caudle; Kristofer S Fritz; James R Roede
Journal:  Parkinsons Dis       Date:  2015-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.